Write in a clean editor, then format for Translational Medicine Communications in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Translational Medicine Communications is a peer-reviewed journal published by BMC (BioMed Central), covering COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Immune Cell Function and Interaction.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Translational Medicine Communications. 2023;12(3):45–58.
Formats any DOI in Translational Medicine Communications style. No sign-up. |
| Publishes research in | COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Immune Cell Function and Interaction Diet and metabolism studies CAR-T cell therapy research |
| ISSN | 2396-832X |
| Citation impact (2-yr) | 2.86 |
| h-index | 21 |
| i10-index | 49 |
| Total citations | 2,113 |
| Article processing charge | $1,827 |
| Top institutions publishing here | An-Najah National University |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Abstract A rift that has opened up between basic research (bench) and clinical research and patients (bed) who need their new treatments, diagnostics and prevention, and this rift is widening and getting deeper. The crisis involving the “translation” of basic scientific findings in a laboratory setting into human applications and potential treatments or biomarkers for…
Abstract Background The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has profoundly affected the lives of millions of people. To date, there is no approved vaccine or specific drug to prevent or treat COVID-19, while the infection is globally spreading at an alarming rate. Because the development…
BACKGROUND: The COVID-19 pandemic remains an emerging public health crisis with serious adverse effects. The disease is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV--2) infection, targeting angiotensin-converting enzyme-2 (ACE2) receptor for cell entry. However, changes in the renin-angiotensin system (RAS) balance alter an individual's susceptibility to COVID-19 infection. We aimed to evaluate the association…
Background: Globally, the healthcare industry is well known to be one of the strongest drivers of economic growth and development. The sector has gained substantial attention to deal with the fallout of COVID-19, leading to improvement in the quality observed in developed and developing nations. With the advent of the twenty-first century, globalization an ever-growing…
BACKGROUND: SARS-CoV-2 and its associated disease, COVID-19, has infected over seven million people world-wide, including two million people in the United States. While many people recover from the virus uneventfully, a subset of patients will require hospital admission, some with intensive care needs including intubation, and mechanical ventilation. To date there is no cure and…
